{"DataElement":{"publicId":"5823145","version":"1","preferredName":"Patient Human Immunodeficiency Virus Positive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study related to Human Immunodeficiency Virus Positive as outlined in the protocol.","longName":"HIV_POS_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5823144","version":"1","preferredName":"Patient Human Immunodeficiency Virus Positive Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME._Confirmation of something, such as a positive lab test. In medicine, a positive lab test indicates the presence of a disease, condition, or microorganism. (NCI)_Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:5823142v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5823142","version":"1","preferredName":"Human Immunodeficiency Virus Positive Clinical Trial Eligibility Criteria","preferredDefinition":"Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.:Confirmation of something, such as a positive lab test. In medicine, a positive lab test indicates the presence of a disease, condition, or microorganism. (NCI):Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C14219:C0205159:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Immunodeficiency Virus","conceptCode":"C14219","definition":"The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Positive","conceptCode":"C0205159","definition":"Confirmation of something, such as a positive lab test. In medicine, a positive lab test indicates the presence of a disease, condition, or microorganism. (NCI)","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F565EED-43E3-3E3B-E053-F662850A2338","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-12","modifiedBy":"ONEDATA","dateModified":"2017-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F565EED-43F4-3E3B-E053-F662850A2338","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-12","modifiedBy":"TAYLORT","dateModified":"2018-02-08","changeDescription":"2/8/18 tt released/form usage. 5/12/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Has eligibility of HIV-positi","type":"Preferred Question Text","description":"Has eligibility of HIV-positive patient who is not on antiviral therapy, has undetectable viral load and CD4 counts greater than 300 been confirmed after discussion with Study Chair.","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If positive for human immunodeficiency virus (HIV), does the patient have the following? a.  A stable regimen of highly active anti-retroviral therapy (HAART) b. No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections c. A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) does patient have: undetectable HIV load by standard PCR clinical assay. Is willing to maintain adherence to combination antiretroviral therapy, has no history of AIDS defining condition (other than lymphoma or CD4 cell count less than 200 mm3), and is likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) does patient have: undetectable HIV load by standard PCR clinical assay, has absolute CD4 count greater than or equal to 200 mm3, Is willing to maintain adherence to combination antiretroviral therapy, has no history of AIDS defining condition (other than lymphoma or CD4 cell count less than 200 mm3), and is likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient is positive for human immunodeficiency virus (HIV) is patient on a stable regimen of highly active anti-retroviral therapy (HAART), has no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections and CD4 count is above 250 cells/mcL, and has an undetectable HIV viral load on standard PCR-based tests?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is HIV positive, does patient have a detectable viral load, is not on a stable antiretroviral regimen, has a decreased CD4+ T-cell count (less than 500) or requires prophylactic antibiotics for the prevention of opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has a history of human immunodeficiency virus (HIV) infection, patient is on an effective antiretroviral therapy and HIV viral load is undetectable within 6 months of study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is HIV-positive, has undetectable viral load, CD4 count is greater than 300 and is not receiving interactive antiretroviral therapy, has eligibility been discussed with the principal investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is HIV-positive, does patient have an undetectable viral load and are able to use anti-viral agents that do not interact with CYP3A4 (or regimens with agents that are not major inhibitors of cytochrome P450 enzymes)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If HIV-infected, is patient on effective antiretroviral regimens utilizing non-CYP-interacting agents, they have an undetectable viral load, they have a CD4 count greater than 350 cells/mm3, and they have no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient is HIV-infected, is viral load undetectable and CD4 count is greater than or equal to 250 cells/mcL within 7 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is HIV-infected, is patient on effective anti-viral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is known to be human immunodeficiency virus (HIV)-positive is CD4 count greater than 350 cells/mm3, viral load is undetectable, patient is maintained on modern therapeutic regimens (utilizing non-CYP-interactive agents) and there is no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient is HIV positive, the following criteria must be met: patient must be on a stable anti-retroviral regimen and be healthy from a HIV perspective; must have a CD4 count greater than 250 cells/mcl; must not be receiving prophylactic therapy for an opportunistic infection.","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is HIV positive, the following criteria must be met: CD4 count greater than 350 cells/mm3, undetectable viral load within the last six months, patient must be stable on HAART, no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient is HIV-infected (HIV 1/2 antibody-positive), have all of the criteria in section 3.1.11 been met?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If HIV-infected, patient may be enrolled on this study provided they meet the following conditions: (a) they are on a stable regimen of highly active anti-retroviral therapy (HAART) with no medications otherwise prohibited by this protocol (e.g. drug-drug interactions) and (b) require no concurrent antibiotics or antifungals for the prevention of opportunistic infections and (c) have a CD4 count above 250 cell/mcL and an undetectable viral load on standard PCR-based tests within 1 month of initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient is HIV-positive, are CD4 counts adequate and there is no requirement for CYP3A4-interactive antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If HIV-infected (HIV1/2 antibody-positive), patient may be enrolled on this study provided they meet the following conditions: (1) They must be on an anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on this same regimen; the most recent undetectable viral load must be within the past 12 weeks (2) They must have a CD4 count greater than or equal to 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count less than 200 cells/ mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy-induced bone marrow suppression (3) They must have an undetectable viral load and a CD4 count greater than or equal to 250 cells/mcL within 7 days of enrolment (4) They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months.","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive have the criteria in section 3.1.11 been met?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is patient Human immunodeficiency virus (HIV) infected?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If HIV-positive, does patient have undetectable HIV viral load less than or equal to 40 copies/mL measured using an FDA-approved commercial assay with lower limit of detection between less than or equal to 20 copies/mL and less than or equal to 40 copies/mL?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV)-positive, does patient meet the criteria in section 3.1.7 of the protocol?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive, does patient meet the criteria in section 3.1.10 of the protocol?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F568F3E-6CEF-1C23-E053-F662850AC2D0","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-12","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeDescription":"2/12/18 semantic correction to definition. 2/8/18 tt released/forms usage. 5/12/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}